Merck KGaA acquires microbiology business of Biotest AG

23 March 2011

Darmstadt -based Merck KGaA (MRK: DE) has entered into a definitive agreement to acquire the microbiology business of fellow German company Biotest AG. Financial terms of the accord were not disclosed. It is planned to integrate Biotest’s microbiology activities into Merck Millipore’s Lab Solutions business unit.

This business comprises heipha Dr Muller GmbH, located in Eppelheim, Germany, as well as the Hycon business located in Dreieich, the subsidiaries in France, Japan and in the USA, as well as further activities and employees in several European countries. In all, the business has about 290 employees and sales of around 50 million euros ($70.7 million) in 2010. The agreement is subject to antitrust approvals in Germany and Austria and is expected in the second half of 2011.

Will add to Merck Millipore offerings

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK